Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2018-02-05T09:26:29+00:00

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Research

Our lead program DMX-200 is advancing through Phase 2 trials in patients with Chronic Kidney Disease (CKD).

Learn More

Technology

Our Receptor Heteromer Investigation Technology (Receptor-HIT) has been used by global pharmaceutical partners, and supported the development of our own DMX-200 program.

Learn More

Investors

Access the latest company news and information

Visit Investor Centre

Recent news and media

Dimerix Recommended as Stock To Watch

Investment Manager Tony Locantro from Alto Capital has recommended Dimerix stock as a good investment on his Bulls, Bears and Brokers [...]

ASX: Further US Patent Application Allowed For DMX-200

Dimerix is pleased to announce the receipt of a Notice of Allowance from the US Patent and Trade Mark Office (USPTO) [...]

2018 Gold Coast Investment Showcase Presentation

CEO Kathy Harrison Presents at the 2018 Gold Coast Investment Showcase

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation

Home
Company
Program
Technology
Investors
Contact

© Copyright 2018 Dimerix | Credits

subscribe to patient updates

subscribe to news updates